OBSOLETE: Metabolic disease associated with ocular features Advocacy Hub | UniteRare

At a Glance

Live from database

1 event

Nov 1998

Sandostatin LAR: FDA approved

Treatment of profuse watery diarrhea associated with VIPoma.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

Sandostatin LAR

Novartis Pharmaceuticals Corporation

OpenContact for detailsApply ↗

No active clinical trials currently recruiting for OBSOLETE: Metabolic disease associated with ocular features.
Search all trials →

No recent news articles indexed yet for OBSOLETE: Metabolic disease associated with ocular features.
Search PubMed for OBSOLETE: Metabolic disease associated with ocular features →

No specialists currently listed for OBSOLETE: Metabolic disease associated with ocular features.

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants